Know Cancer

or
forgot password

Clinical Testing of a Decision Support System for Tobacco Use Treatment


Phase 2
18 Years
N/A
Open (Enrolling)
Both
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder

Thank you

Trial Information

Clinical Testing of a Decision Support System for Tobacco Use Treatment


OBJECTIVES:

- Test the hypothesis that the clinical decision support system will improve the rate at
which physicians assist their patients with smoking cessation by providing information
and recommendations on smoking cessation resources.

- Assess whether exposure to information and recommendations facilitated by the smoking
cessation-personal digital assistant (SC-PDA) will increase the rate at which patients
make at least 1 attempt to quit smoking in the month following the physician visit.

- Assess whether exposure to information and recommendations facilitated by the SC-PDA
will increase the reported use of counseling and pharmacotherapy during those attempts
over that observed with a smoking status identification system alone.

- Evaluate the acceptance of the SC-PDA into the workflow of ambulatory care clinics.

OUTLINE: In weeks 1-12, physicians have access to a smoking status identification system
(SSID) that reminds the physician the smoking status of the patient they are evaluating. In
weeks 6-12, physicians have access to a computerized smoking cessation clinical decision
support system using a hand-held personal digital assistant (SC-PDA) that they can use in
the exam room with their patients who smoke. The SC-PDA system assists physicians in
recommending and prescribing approved pharmacotherapy; facilitates referral of patients to
local counseling resources; prints a tailored handout for a patient listing specific
recommendations, instructions, and cessation resources; and generates the necessary
documentation to support billing for this intervention.

Patients who visit their physician in weeks 2-6 or weeks 8-12 complete a survey after their
clinic visit and undergo a telephone interview 1 month later. Physicians undergo interviews
and focus groups are conducted with clinic staff in weeks 12-16.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Current smoker, defined as self-reported smoking most days or every day (patient)

- Seeks care at a participating Fletcher Allen Health Care primary care clinic
(patient)

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- Not specified

Type of Study:

Interventional

Study Design:

Primary Purpose: Health Services Research

Outcome Measure:

Physician adherence to the United States Public Health Service's Tobacco Use and Dependence Treatment guideline (USPHS Guideline) as measured by the patient exit survey

Safety Issue:

No

Principal Investigator

Theodore W. Marcy, MD, MPH

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Vermont

Authority:

Unspecified

Study ID:

CDR0000629824

NCT ID:

NCT00865553

Start Date:

March 2009

Completion Date:

Related Keywords:

  • Bladder Cancer
  • Cervical Cancer
  • Esophageal Cancer
  • Gastric Cancer
  • Head and Neck Cancer
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Pancreatic Cancer
  • Tobacco Use Disorder
  • bladder cancer
  • cervical cancer
  • esophageal cancer
  • gastric cancer
  • renal cell carcinoma
  • adult primary liver cancer
  • non-small cell lung cancer
  • small cell lung cancer
  • pancreatic cancer
  • hypopharyngeal cancer
  • laryngeal cancer
  • lip and oral cavity cancer
  • nasopharyngeal cancer
  • oropharyngeal cancer
  • paranasal sinus and nasal cavity cancer
  • adult acute myeloid leukemia
  • tongue cancer
  • tobacco use disorder
  • Urinary Bladder Neoplasms
  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Uterine Cervical Neoplasms
  • Esophageal Diseases
  • Esophageal Neoplasms
  • Head and Neck Neoplasms
  • Leukemia
  • Liver Neoplasms
  • Lung Neoplasms
  • Stomach Neoplasms
  • Pancreatic Neoplasms
  • Tobacco Use Disorder

Name

Location

Vermont Cancer Center at University of Vermont Burlington, Vermont  05405-0075